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C
oronary artery disease is the most common cause of congestive heart failure. More than
70% of the patients with heart failure symptoms have underlying coronary disease, whereas
the majority of patients with ischaemic cardiomyopathy have a previous myocardial
infarction.1 2 The prognosis of these patients is poor, particularly in men, and many of them need
intermittent hospitalisation because of decompensated heart failure. In the near future, chronic
heart failure will be encountered even more often, as our population ages.1 2 The clinical charac-
teristics of the patient, the presence of ischaemia, and severity of left ventricular dysfunction
determine the prognosis in heart failure.
Traditionally, ischaemic left ventricular dysfunction was considered an irreversible process. In
patients with ischaemic cardiomyopathy, medical treatment was regarded as the only manage-
ment option. However, more than two decades ago, Diamond and Rahimtoola recognised that
left ventricular dysfunction in these patients is not always permanent and launched the theory
of myocardial hibernation.3 4 Hibernating myocardium is defined as chronic reversible con-
tractile dysfunction secondary to coronary artery disease. The presence of hibernating myo-
cardium has become an additional motive to perform coronary revascularisation. In fact, if a
substantial amount of hibernating myocardium is present, coronary revascularisation may
substantially improve regional and global contractile function in selected patients with ischaemic
cardiomyopathy.5
This article will focus on the clinical importance and identification of myocardial viability in
patients with chronic ischaemic left ventricular dysfunction.
PATHOPHYSIOLOGY OF VIABLE MYOCARDIUMc
In patients with ischaemic cardiomyopathy several (patho)physiological conditions of the
myocardium may coexist. Often there are areas with preserved contractile function supplied by
coronary arteries without significant stenoses. On the other hand, contractile dysfunction can be
observed in myocardial regions that are subtended by a stenotic or occluded coronary artery.
Coronary occlusion may cause cellular death resulting in irreversibly scarred myocardium.6
Alternatively, the reduced contractile function may be a result of adaptation to an (intermittent)
reduction in blood flow. This physiological down-regulation of contractile function, also referred
to as myocardial hibernation, may be an adequate response to myocardial ischaemia, to protect
myocytes from irreversible damage. Biopsy samples obtained during coronary bypass surgery
demonstrate that hibernating myocardium is characterised by a loss of contractile proteins,
whereas cell membrane and cellular metabolism remain intact.7 Restoration of blood flow by
coronary revascularisation may result in recovery of contractile function in hibernating myo-
cardium. The time course of functional recovery of hibernating myocardium may vary con-
siderably,8 and depends on several factors including the duration and severity of myocardial
ischaemia, the time and completeness of myocardial revascularisation, and the extent of ultra-
structural alterations within the dysfunctional myocardium. Less severely damaged myocardium
may improve within three months of revascularisation, in contrast to severely damaged tissue,
which may take more than one year to fully recovery in function after revascularisation.
Besides hibernating myocardium, patients with ischaemic cardiomyopathy often have some
regions that contain (chronically) stunned myocardium. Myocardial stunning is characterised by
a depressed contractile function in the presence of normal resting blood flow,6 and may occur as a
result of repetitive ischaemic episodes.
HOW TO ASSESS MYOCARDIAL VIABILITY?
Some information can be derived from the ECG, but imaging is clearly preferred. Several non-
invasive imaging techniques have been developed to identify dysfunctional but viable tissue:
dobutamine stress echocardiography, single photon emission computed tomography (SPECT)
imaging with thallium-201 or technetium-99 m labelled tracers, and positron emission tomo-
graphy (PET) metabolic imaging with F18-fluorodeoxyglucose (FDG). These techniques evaluate
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different characteristics of viable myocardium and can
delineate irreversibly scarred from dysfunctional but viable
myocardium (table 1).
The ECG
The ECG has the obvious advantage of a widespread
availability and limited costs, but there is no clear correlation
between Q waves on ECG and the presence of viable or non-
viable myocardium. Also, the relation between ST segment
changes (in particular ST segment elevation) during stress
testing and myocardial viability is not entirely clear. However,
QT dispersion is related to the presence of myocardial viabi-
lity in patients with ischaemic cardiomyopathy. Patients with
preserved QT dispersion are likely to have a substantial
amount of viable myocardium, whereas patients with a high
QT dispersion have predominantly non-viable scar tissue.
Echocardiographic techniques
Resting echocardiography
From the resting images, an initial impression concerning the
absence of viability can be derived. A pronounced end dias-
tolic wall thinning virtually excludes the presence of viable
tissue.9 In patients without a clear thinning of the dysfunc-
tional area, low dose dobutamine echocardiography can be
performed to evaluate myocardial viability.
Dobutamine stress echocardiography
Dobutamine stress echocardiography is a widespread and
relatively inexpensive method to assess myocardial viability
(fig 1). Dysfunctional but viable myocardium is characterised
by preserved contractile reserve during dobutamine echocar-
diography.10 In hypokinetic or akinetic regions, an improve-
ment of contraction during low dose dobutamine infusion
(5–10 mg/kg/min) is indicative of viable tissue. To improve
the assessment of viability, the low dose dobutamine protocol
may be extended by high dose dobutamine stress (with
dosages up to 40 mg/kg/min and the addition of atropine).
This protocol allows assessment of the biphasic response: an
initial improvement of contractility during low dose dobuta-
mine stress and worsening of contractile function during
high dose dobutamine infusion caused by stress induced
ischaemia. This response is highly predictive of recovery of
function after revascularisation. Dobutamine stress echocar-
diography is a safe test in patients with ischaemic cardio-
myopathy; the most common side effects are hypotension
and self limiting arrhythmias.
Tissue Doppler imaging
Tissue Doppler imaging was developed to overcome the
subjective nature of the echocardiographic examination.
Tissue Doppler imaging allows quantification of myocardial
function using the Doppler shift principle. Tissue Doppler
images may be displayed as colour encoded velocity profiles
in M mode and two dimensional imaging formats. For
viability assessment tissue Doppler echocardiography may be
combined with low dose dobutamine infusion. In dysfunc-
tional but viable myocardium, baseline tissue velocity is
impaired, and myocardial velocities increase during dobuta-
mine infusion. The major advantage of this technique is the
high spatial and temporal resolution. Rambaldi and collea-
gues11 compared pulsed wave tissue Doppler imaging with
dobutamine stress echocardiography in 40 patients with
ischaemic cardiomyopathy, using FDG imaging as the gold
standard for viability assessment. Tissue Doppler imaging
resulted in a significant increase in sensitivity of dobutamine
echocardiography to detect viable myocardium.
Contrast echocardiography
Two dimensional echocardiography may be combined with
intravenous contrast administration to assess both myocar-
dial function and myocardial perfusion in real time (fig 2). A
bolus of contrast is intravenously injected followed by a
saline flush. Echocardiography using a low mechanical index
is started before contrast injection and subsequently ‘‘flash’’
imaging with high mechanical index is used at peak contrast
intensity to destroy the microbubbles in the myocardium, to
avoid artefacts and to visualise myocardial contrast replenish-
ment. Because contrast echocardiography allows simultaneous
assessment of function and perfusion, stunned myocar-
dium can be distinguished from hibernation. Shimoni and
colleagues12 studied the accuracy of contrast echocardiography
in 20 patients with coronary disease and left ventricular
dysfunction who underwent bypass surgery. Optimal identi-
fication of viable myocardium was obtained when perfusion
as assessed by contrast echocardiography was analysed
quantitatively.
Nuclear techniques: SPECT
Thallium-201
Thallium-201 is a cationic c emitter, which is taken up by the
myocardium similarly to potassium. The early uptake of
thallium-201 is proportional to regional blood flow, whereas
delayed uptake indicates a preserved sodium–potassium
pump and an intact cell membrane. Several protocols have
been developed to evaluate myocardial viability including
stress–redistribution–reinjection and rest–redistribution. Dil-
sizian and colleagues13 demonstrated that reinjection of
thallium-201 following acquisition of the redistribution
images may further improve the detection of viable myocar-
dium. Because the stress–redistribution–reinjection techni-
que is labour intensive and requires three image acquisitions,
many nuclear cardiology laboratories use shorter, modified
imaging protocols. Exercise is the first choice stressor,
because exercise capacity itself provides prognostic informa-
tion. In patients unable to perform an exercise test, phar-
macological stress can be used.
Technetium-99 m labelled tracers
Technetium-99 m labelled tracers (technetium-99 m sesta-
mibi, technetium-99 m tetrofosmin) can be used to assess
perfusion and intact mitochondria. The shorter half life
Table 1 Characteristics of dysfunctional but viable
myocardium
Characteristic Technique Signs of viability
Contractile reserve Dobutamine
echocardiography,
dobutamine MRI
Improved contraction
during infusion of low dose
dobutamine
Intact cell membrane Thallium-201 SPECT Tracer activity .50%
Redistribution (.10%)
Intact mitochondria Technetium-99 m
SPECT
Tracer activity .50%
Improved tracer uptake
after nitrates
Glucose metabolism FDG imaging Tracer activity .50%
Preserved perfusion/FDG
uptake
Perfusion–metabolism
mismatch
FDG, F18-fluorodeoxyglucose; MRI, magnetic resonance imaging;
SPECT, single photon emission computed tomography.
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allows the use of higher dosages than for thallium-201, and
in combination with the higher photon energy, excellent
image quality can be obtained with the technetium-99 m
labelled agents. A major advantage is that the recent
technical developments have resulted in gated imaging
allowing simultaneous assessment of myocardial perfusion
and contractile function. Currently, gating is performed in
the majority of studies with the technetium-99 m labelled
agents. Several studies have shown that technetium-99 m
labelled tracers may underestimate myocardial viability as
compared to FDG PET. However, more recent studies have
shown that viability assessment using technetium-99 m
labelled tracers can be improved by administration of
nitrates.
Nuclear techniques: PET
FDG to assess glucose uti l isation
Generally, glucose utilisation is evaluated with the glucose
analogue FDG and compared to regional myocardial perfu-
sion assessed with N13-ammonia, rubidium-82, or O15-
labelled water.14–17 A normal perfusion and FDG uptake, or
reduced perfusion with enhanced FDG uptake (mismatch
pattern), indicates viable myocardium. Conversely, a con-
cordant reduction in FDG uptake and myocardial perfusion
(match pattern) is indicative of scar tissue. PET is often
considered the reference technique for the assessment of
myocardial viability, because of the quantitative results, high
spatial resolution, and good correlation with outcome after
coronary revascularisation.14–17 The introduction of SPECT
using dedicated (511 keV) collimators (fig 3) has contributed
to a more extensive use of metabolic imaging, since PET
facilities are limited and relatively expensive. Several studies
have demonstrated that FDG SPECT and FDG PET imaging
have a comparable diagnostic accuracy for the assessment of
myocardial viability.18
Alternative PET techniques
Besides FDG imaging, PET may be combined with C11-
acetate to assess residual oxidative metabolism. Clearance
rates of C11-acetate from dysfunctional myocardium reflect
the rate of oxidative phosphorylation. The rate of oxidative
metabolism has been demonstrated to correlate closely to
improvement of function after myocardial revascularisation.
Gropler and colleagues15 studied 34 patients with coronary
artery disease and compared C11-acetate PET with FDG PET
for prediction of functional recovery after revascularisation.
Assessment of regional oxidative metabolism by PET with
C11-acetate was an accurate predictor of functional recovery,
and was slightly more accurate than FDG PET.
Figure 1 Transthoracic two
dimensional echocardiogram (apical
four chamber view, end systolic) at rest
(left panel) and during infusion of low
dose dobutamine (right panel) in a
patient with ischaemic cardiomyopathy
and severe hypokinesia of the septum
and lateral wall. During low dose
dobutamine, improved contraction of
the dysfunctional segments indicates
myocardial viability.
Figure 2 Transthoracic two
dimensional echocardiogram after
intravenous injection of a contrast agent
(apical four chamber view).
Opacification of the left ventricular
cavity after administration of the contrast
agent facilitates endocardial border
delineation (left panel). Subsequently, a
destruction–fill method can be used to
assess myocardial perfusion. In this
example, a perfusion defect was present
in the hypokinetic lateral wall.
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Rubidium-82 (Rb82) is another PET tracer, which allows
assessment of both myocardial perfusion and cell membrane
integrity. Yoshida and Gould16 evaluated a large cohort of
patients with Rb82 and demonstrated that the prognosis of
patients with chronic ischaemic left ventricular dysfunction
was dependent on both the infarct size and the extent of
viability, as derived from the Rb82 images.
PET also allows non-invasive assessment of the water
perfusable tissue fraction (PTF). This parameter is derived
from quantification of myocardial blood flow using 15O-water
(H2
15O). Information on the accuracy of PTF for the pre-
diction of functional recovery is still limited. Bax and
colleagues17 studied 34 patients with ischaemic cardiomyo-
pathy who underwent myocardial revascularisation with
both 15O-water and FDG PET to compare the relative merits
of myocardial blood flow (MBF), metabolic rate of glucose
(MRG, absolute and relative), and PTF. High sensitivities for
the prediction of improvement of left ventricular ejection
fraction after revascularisation were observed for all PET
indexes, whereas the specificities of the various techniques
were somewhat lower.
Magnetic resonance imaging
Recently, magnetic resonance imaging (MRI) was introduced
to evaluate myocardial viability. Currently, three techniques
are being used:
c resting MRI to measure end diastolic wall thickness
c dobutamine MRI to evaluate contractile reserve
c contrast enhanced MRI to detect the extent and trans-
murality of scar tissue.
Resting MRI
Resting MRI can be used to assess end diastolic wall
thickness and contractile function at rest. Several studies
have demonstrated that segments with an end diastolic wall
thickness , 6 mm most likely represent transmural scar
formation and contractile function will not improve after
myocardial revascularisation. However, dysfunctional seg-
ments with a preserved wall thickness will not always recover
after revascularisation. This may be related to the presence of
subendocardial scar in these segments. Therefore, additional
testing is needed to predict outcome in the segments with
preserved end diastolic wall thickness.
Dobutamine MRI
Dobutamine MRI can be used to evaluate contractile reserve,
in a similar manner to dobutamine echocardiography.19 The
major advantage of MRI over echocardiography is the
increased resolution of MRI, allowing for quantitative assess-
ment of wall thickening during dobutamine infusion, and
thus avoiding the subjective analysis of echocardiography.
Baer and colleagues have initially demonstrated an excellent
agreement between dobutamine MRI and FDG PET19; in a
subsequent study the authors reported a sensitivity of 89%
with a specificity of 94% to predict improvement in resting
function after revascularisation.20
Contrast enhanced MRI
When combined with gadolinium based contrast agents, MRI
allows precise detection of scar tissue. Animal experiments
have demonstrated an excellent correlation between the
extent and transmurality of scar tissue and contrast enhan-
cement on MRI.21 Due to the high spatial resolution, MRI is
currently the only technique that permits evaluation of the
different myocardial layers and contrast enhanced imaging
makes detection of subendocardial scar tissue possible (fig 4).
Klein and colleagues22 compared contrast enhanced MRI
with FDG PET in 31 patients with ischaemic cardiomyo-
pathy and showed an excellent agreement between the two
techniques to detect scar tissue. More recently, Kim and
colleagues23 applied contrast enhanced MRI in 41 patients
with chronic left ventricular dysfunction undergoing revas-
cularisation. The authors demonstrated that the likelihood of
improvement in regional contractility after revascularisation
Figure 3 Dual isotope simultaneous
acquisition SPECT scan (horizontal long
axis slices) showing a substantial
perfusion–metabolism mismatch in the
inferior wall, indicating viable
myocardium.
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progressively decreased as the transmural extent of hyper-
enhancement increased.
Electromechanical mapping to assess viabili ty
Electromechanical assessment of myocardial viability has
been developed using the NOGA system, a catheter based,
non-fluoroscopic, three dimensional endocardial mapping
system. Based on integrated assessment of function and
electrical activity, delineation of dysfunctional but viable
myocardium is possible. When a threshold amplitude of
7.5 mV was used, the sensitivity and specificity for detecting
viable myocardium were 77% and 75%.24 Electromechanical
mapping is not the technique of choice to assess viability in a
diagnostic setting, but may be useful as a platform for
additional procedures. For example, electromechanical map-
ping may be used to assess viability and generate three
dimensional left ventricular reconstruction before laser
revascularisation, intramyocardial gene transfer, or myoblast
injection.25
CLINICAL IMPORTANCE OF VIABILITY ASSESSMENT
Patients with heart failure symptoms caused by ischaemic
cardiomyopathy represent a high risk group. In various
registries of patients with left ventricular dysfunction, the
one year mortality rates range from 15–40%.1 2 To improve
clinical outcome in these patients, several treatment options
have been developed. Patients with ischaemic cardiomyo-
pathy deserve careful evaluation and treatment needs to be
tailored to the individual patient. Significant progress in
the management of ischaemic cardiomyopathy has been
achieved with medical treatment, including angiotensin
converting enzyme inhibitors, spironolactone, and low dose
b blocking agents.26–28 However, medical treatment is still
associated with a suboptimal prognosis in patients with
ischaemic cardiomyopathy. Heart transplantation is asso-
ciated with a favourable survival, but the availability of donor
hearts is limited. Many patients who are eligible for trans-
plantation will not receive a donor heart and die awaiting
transplantation. Coronary revascularisation may be a good
alternative treatment for the subgroup of patients with a
substantial amount of dysfunctional but viable myocardium.5
Recent studies have demonstrated that in more than 50% of
patients with ischaemic cardiomyopathy, a clinically signifi-
cant amount of viable myocardium is present. In these
patients, revascularisation may improve, and even normalise,
left ventricular ejection fraction, heart failure symptoms,
exercise capacity, and survival. Moreover, data from 258
consecutive patients indicated that recovery of global func-
tion can be anticipated after myocardial revascularisation in
almost 40% of patients with ischaemic cardiomyopathy.29
These observations indicate the need for a careful analysis of
patients with heart failure (even in the absence of angina
pectoris) including assessment of viability, on a routine basis.
Two dimensional echocardiography is an excellent first step
to assess regional and global contractile function and valvar
function. Myocardial stress imaging can then be used to
evaluate ischaemia, followed by coronary angiography to
assess the extent and severity of coronary artery disease and
also evaluate whether the coronary anatomy is amendable for
coronary revascularisation. Finally, viability testing should be
performed using one of the non-invasive imaging techniques,
and based on the findings, the treatment can be tailored to
the individual patient.
All the aforementioned techniques have been studied
extensively, although most expertise has been obtained with
dobutamine stress echocardiography and nuclear imaging.
Pooled analysis of available data of the five most frequently
used techniques to assess viability is summarised in table 2.
In general, the nuclear imaging techniques appear to have
a higher sensitivity for the prediction of functional reco-
very whereas stress echocardiography appears to be more
specific.30 The difference between nuclear imaging and
Figure 4 Contrast enhanced MRI in a patient with an anterior wall
infarction.
Table 2 Accuracy of non-invasive techniques to assess myocardial viability
Technique
Number of
studies
Number of
patients
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
DSE 32 1090 81 80 77 85
Tl-201 RR 22 557 86 59 69 80
Tl-201 RI 11 301 88 50 57 83
MIBI 20 488 81 66 71 77
FDG PET 20 598 93 58 71 86
Based on pooled analysis of data available in the literature.29
DSE, dobutamine stress echocardiography; FDG, F18-fluorodeoxyglucose; MIBI, technetium-99 m sestamibi; NPV,
negative predictive value; PET, positron emission tomography; PPV, positive predictive value; RR, rest–
redistribution; RI, reinjection; Tl-201, thallium-201 chloride.
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dobutamine stress echocardiography for the prediction of
functional improvement after myocardial revascularisation is
even more outspoken when only direct comparative studies
are considered.30 Pooling of head-to-head comparisons
underscores the differences in sensitivity and specificity of
dobutamine stress echocardiography and thallium-201
SPECT (fig 5). The discrepancy between nuclear imaging
and dobutamine echocardiography for the prediction of
functional outcome after revascularisation may be related
to different levels of ultrastructural cell damage in dysfunc-
tional myocardium. The inotropic response during dobuta-
mine stimulation may no longer be intact while more basal
characteristics such as cell membrane integrity and glucose
utilisation are still preserved. Based on these observations,
nuclear imaging may be preferred in patients with depressed
left ventricular ejection fraction and severely damaged
myocardium.
How much viable tissue is needed for improvement of
function?
The extent of improvement in global function is related to the
extent of dysfunctional but viable tissue. Several studies have
demonstrated that a certain amount of dysfunctional but
viable tissue is needed for an improvement of global function
following revascularisation. Usually a cut-off level of > 4
viable segments in a 16 segment model of the left ventricle is
advised as a cut-off value to predict improvement of left
ventricular ejection fraction.5 This cut-off value represents
approximately 25% of the left ventricle, and may be used to
identify patients who may benefit from revascularisation.
However, this cut-off value of viable segments is to some
extent artificial, because other factors also influence recovery
of function. Recent data indicate that in patients with
ischaemic cardiomyopathy and a mixture of viable and
non-viable tissue, the extent of scar tissue should also be
taken into account in order to predict accurately functional
recovery after revascularisation.31 In addition, remodelling
and enlargement of the left ventricle should also be
considered. Remodelling of the left ventricle resulting in an
enlarged end systolic volume may prevent global recovery,
even in patients with substantial viability.32 Consideration of
these issues and integration into a mathematical model may
further improve patient selection for revascularisation.
Moreover, the surgical therapeutic options are developing
rapidly, and myocardial revascularisation can now be
combined with additional mitral valve repair to further
optimise outcome. Also, resection of left ventricular aneur-
ysms can be considered in the presence of extensive scar
formation.
CONCLUSION
With the increasing number of patients presenting with
ischaemic cardiomyopathy, assessment of myocardial hiber-
nation and prediction of functional recovery after myocardial
revascularisation have become common clinical issues. A
number of non-invasive imaging techniques has been deve-
loped to identify hibernating myocardium. Although the ECG
and resting echocardiogram may provide some initial clues
on the presence/absence of viable myocardium, more sophis-
ticated imaging techniques are usually needed. Both dobu-
tamine stress echocardiography and nuclear imaging have
been extensively used for the assessment of hibernating
myocardium, and newer techniques such as MRI may further
enhance the assessment of viability. Besides assessment of
viability, additional factors need to be considered to allow
precise prediction of outcome, including the presence and
extent of scar tissue, the severity of remodelling of the left
ventricle, and the presence of concomitant mitral regurgita-
tion. Integrated information on all these issues will optimise
patient selection for surgery, resulting in improved outcome
and long term survival after revascularisation.
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